Literature DB >> 20109112

Proteome analysis of schizophrenia brain tissue.

Daniel Martins-De-Souza1, Emmanuel Dias-Neto, Andrea Schmitt, Peter Falkai, Philipp Gormanns, Giuseppina Maccarrone, Christoph W Turck, Wagner F Gattaz.   

Abstract

OBJECTIVES: Proteome analysis has emerged as a promising strategy to the identification of potential biomarkers and to further confirm the importance of certain pathways in the schizophrenia (SCZ) pathophysiology. Reviewing the results of 13 proteome studies in SCZ brain tissue, we aimed to provide information regarding potential proteins biomarkers as well as information about the pathophysiology of the disease. METHODS AND
RESULTS: Using two-dimensional gel electrophoresis and shotgun mass spectrometry, 31 proteins were consistently found differentially expressed in the brains of SCZ patients. The most frequent protein alterations reported in SCZ were related to brain energy metabolism, brain plasticity, and synaptic function, processes that are thought to belong to the core of the biology of this disease. The recurrent identification and validation of inter-related protein clusters, determined in different samples and approaches, strongly reinforces the putative involvement of certain pathways in SCZ.
CONCLUSIONS: The availability of reliable markers not only paves the way to the development of new therapeutic strategies but also points out the possibility of their use as peripheral blood markers that may potentially contribute to the early SCZ detection and early therapeutic intervention, both of which can reduce the social and cognitive consequences of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109112     DOI: 10.3109/15622970903490626

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  29 in total

Review 1.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia.

Authors:  Daniel Martins-de-Souza; Maria Lebar; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-11-19       Impact factor: 5.270

Review 3.  Approaches for targeted proteomics and its potential applications in neuroscience.

Authors:  Sumit Sethi; Dipti Chourasia; Ishwar S Parhar
Journal:  J Biosci       Date:  2015-09       Impact factor: 1.826

Review 4.  CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases.

Authors:  T T Quach; J Honnorat; P E Kolattukudy; R Khanna; A M Duchemin
Journal:  Mol Psychiatry       Date:  2015-06-16       Impact factor: 15.992

5.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

6.  Proteomics tackling schizophrenia as a pathway disorder.

Authors:  Daniel Martins-de-Souza
Journal:  Schizophr Bull       Date:  2012-07-30       Impact factor: 9.306

7.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

Review 8.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

Review 9.  Mitochondrial dysfunction in schizophrenia: an evolutionary perspective.

Authors:  Vanessa F Gonçalves; Ana C Andreazza; James L Kennedy
Journal:  Hum Genet       Date:  2014-10-14       Impact factor: 4.132

10.  The diagnosis of depression: current and emerging methods.

Authors:  Katie M Smith; Perry F Renshaw; John Bilello
Journal:  Compr Psychiatry       Date:  2012-08-15       Impact factor: 3.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.